A new edition of the WHO classification of tumours of the CNS was published in 2021.
Although the previous edition of this classification was published just 5 years earlier, in …

Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a
formidable challenge due to its immunosuppressive microenvironment, thereby confounding …

Background Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas are malignant brain
tumors that cause considerable disability and premature death. Vorasidenib, an oral brain …

Chimeric antigen receptor T cell (CAR-T) therapy is an emerging strategy to improve
treatment outcomes for recurrent high-grade glioma, a cancer that responds poorly to current …

PURPOSE The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade
gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve …

Background Nearly all patients with newly diagnosed glioblastoma experience recurrence
following standard-of-care radiotherapy (RT)+ temozolomide (TMZ). The purpose of the …

Background Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival
(OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with …

A better understanding of transcriptional evolution of IDH-wild-type glioblastoma may be
crucial for treatment optimization. Here, we perform RNA sequencing (RNA-seq)(n= 322 test …

Molecular classification has transformed the management of brain tumors by enabling more
accurate prognostication and personalized treatment. However, timely molecular diagnostic …

Background Terminology to describe extent of resection in glioblastoma is inconsistent
across clinical trials. A surgical classification system was previously proposed based upon …